Threshold Pharmaceuticals Company Profile (NASDAQ:THLD)

About Threshold Pharmaceuticals (NASDAQ:THLD)

Threshold Pharmaceuticals logoThreshold Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of therapeutic and diagnostic agents that selectively target tumor cells for the treatment of patients living with cancer. It is developing two therapeutic product candidates based on hypoxia-activated prodrug technology: evofosfamide and tarloxotinib. Evofosfamide is designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not in healthy tissues. Tarloxotinib is under investigation in two Phase II proof-of-concept trials: one for the treatment of patients with mutant EGFR-positive, T790M-negative advanced NSCLC progressing on an EGFR TKI, and the other for patients with recurrent or metastatic squamous cell carcinomas of the head and neck. [18F]-HX4 is an investigational Positron Emission Tomography imaging agent for hypoxia to identify and quantify the degree of hypoxia in tumors in vivo.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:THLD
  • CUSIP: 88580720
  • Web:
  • Market Cap: $35.07 million
  • Outstanding Shares: 71,591,000
Average Prices:
  • 50 Day Moving Avg: $0.44
  • 200 Day Moving Avg: $0.52
  • 52 Week Range: $0.35 - $1.48
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.26
  • P/E Growth: 0.000
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.21 per share
  • Price / Book: 2.29
  • EBIDTA: ($20,290,000.00)
  • Return on Equity: -105.02%
  • Return on Assets: -81.96%
  • Current Ratio: 9.03%
  • Quick Ratio: 9.03%
  • Average Volume: 575,102 shs.
  • Beta: 3.26
  • Short Ratio: 4.97
Frequently Asked Questions for Threshold Pharmaceuticals (NASDAQ:THLD)

What is Threshold Pharmaceuticals' stock symbol?

Threshold Pharmaceuticals trades on the NASDAQ under the ticker symbol "THLD."

How were Threshold Pharmaceuticals' earnings last quarter?

Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) issued its earnings results on Monday, May, 15th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.08) by $0.01. View Threshold Pharmaceuticals' Earnings History.

When will Threshold Pharmaceuticals make its next earnings announcement?

Threshold Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, July, 31st 2017. View Earnings Estimates for Threshold Pharmaceuticals.

Where is Threshold Pharmaceuticals' stock going? Where will Threshold Pharmaceuticals' stock price be in 2017?

1 equities research analysts have issued 1-year target prices for Threshold Pharmaceuticals' stock. Their forecasts range from $0.52 to $0.52. On average, they anticipate Threshold Pharmaceuticals' share price to reach $0.52 in the next year. View Analyst Ratings for Threshold Pharmaceuticals.

Who are some of Threshold Pharmaceuticals' key competitors?

Who are Threshold Pharmaceuticals' key executives?

Threshold Pharmaceuticals' management team includes the folowing people:

  • Harold E. Selick Ph.D., Chairman of the Board
  • Wilfred E. Jaeger M.D., Interim Chief Executive Officer, Independent Director
  • Joel A. Fernandes, Vice President - Finance, Controller
  • Mark Hopkins J.D. Ph.D., Vice President - Intellectual Property and Assistant General Counsel
  • Kristen Quigley, Vice President - Clinical Operations
  • Tillman Pearce M.D., Chief Medical Officer
  • Jeffrey W. Bird M.D. Ph.D., Independent Director
  • Bruce C. Cozadd, Independent Director
  • David R. Hoffmann, Independent Director
  • George G. C. Parker Ph.D., Independent Director

How do I buy Threshold Pharmaceuticals stock?

Shares of Threshold Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Threshold Pharmaceuticals' stock price today?

One share of Threshold Pharmaceuticals stock can currently be purchased for approximately $0.49.

MarketBeat Community Rating for Threshold Pharmaceuticals (NASDAQ THLD)
Community Ranking:  3.7 out of 5 (  )
Outperform Votes:  85 (Vote Outperform)
Underperform Votes:  31 (Vote Underperform)
Total Votes:  116
MarketBeat's community ratings are surveys of what our community members think about Threshold Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Threshold Pharmaceuticals (NASDAQ:THLD) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $0.52 (6.14% upside)

Analysts' Ratings History for Threshold Pharmaceuticals (NASDAQ:THLD)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/3/2016William BlairReiterated RatingOutperformN/AView Rating Details
9/30/2016S&P Equity ResearchLower Price Target$0.67 -> $0.52N/AView Rating Details
12/7/2015Piper Jaffray CompaniesDowngradeOverweight -> NeutralN/AView Rating Details
12/7/2015Cowen and CompanyDowngradeOutperform -> Market PerformN/AView Rating Details
12/7/2015Stifel NicolausDowngradeBuy -> HoldN/AView Rating Details
10/5/2015Cantor FitzgeraldReiterated RatingBuy$14.00N/AView Rating Details
9/15/2015Royal Bank Of CanadaReiterated RatingBuyN/AView Rating Details
(Data available from 7/24/2015 forward)


Earnings History for Threshold Pharmaceuticals (NASDAQ:THLD)
Earnings by Quarter for Threshold Pharmaceuticals (NASDAQ:THLD)
Earnings History by Quarter for Threshold Pharmaceuticals (NASDAQ THLD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/31/2017($0.07)N/AView Earnings Details
5/15/2017Q1 2017($0.08)($0.07)ViewN/AView Earnings Details
3/27/2017Q4 2016($0.07)($0.05)ViewN/AView Earnings Details
11/7/2016Q3($0.09)($0.08)ViewN/AView Earnings Details
8/1/2016Q216($0.10)($0.10)ViewN/AView Earnings Details
5/5/2016Q1($0.02)($0.11)ViewN/AView Earnings Details
3/10/2016Q4($0.11)$0.86$4.51 million$65.87 millionViewN/AView Earnings Details
11/2/2015Q315($0.14)($0.09)$3.69 million$3.70 millionViewN/AView Earnings Details
7/30/2015Q2($0.14)($0.12)$3.70 million$3.68 millionViewN/AView Earnings Details
4/30/2015($0.14)($0.17)$3.44 million$3.68 millionViewN/AView Earnings Details
3/3/2015Q414($0.13)($0.12)$4.34 million$3.68 millionViewN/AView Earnings Details
11/3/2014Q314($0.12)($0.15)$3.82 million$3.70 millionViewN/AView Earnings Details
8/1/2014($0.13)($0.12)$4.00 million$3.68 millionViewN/AView Earnings Details
5/1/2014($0.10)($0.12)$9.81 million$3.68 millionViewN/AView Earnings Details
3/6/2014Q413($0.10)($0.13)$3.58 million$3.20 millionViewN/AView Earnings Details
11/4/2013Q313($0.14)$0.02$3.15 million$3.20 millionViewN/AView Earnings Details
5/2/2013Q1 2013($0.09)($0.16)$2.80 million$2.90 millionViewN/AView Earnings Details
11/2/2012Q312($0.06)($0.06)$2.29 million$1.80 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Threshold Pharmaceuticals (NASDAQ:THLD)
2017 EPS Consensus Estimate: ($0.24)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.06)($0.06)($0.06)
Q2 20171($0.06)($0.06)($0.06)
Q3 20171($0.06)($0.06)($0.06)
Q4 20171($0.06)($0.06)($0.06)
(Data provided by Zacks Investment Research)


Dividend History for Threshold Pharmaceuticals (NASDAQ:THLD)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Threshold Pharmaceuticals (NASDAQ:THLD)
Insider Ownership Percentage: 12.97%
Institutional Ownership Percentage: 24.39%
Insider Trades by Quarter for Threshold Pharmaceuticals (NASDAQ:THLD)
Institutional Ownership by Quarter for Threshold Pharmaceuticals (NASDAQ:THLD)
Insider Trades by Quarter for Threshold Pharmaceuticals (NASDAQ:THLD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/1/2017Jeffrey W BirdDirectorBuy510,703$0.57$291,100.71View SEC Filing  
2/18/2015Wilfred E JaegerDirectorBuy25,000$3.75$93,750.00View SEC Filing  
10/13/2014Nipun DavarVPBuy3,000$2.99$8,970.00View SEC Filing  
10/1/2014Hill Ventures SutterMajor ShareholderSell226,657$3.77$854,496.89View SEC Filing  
10/1/2014Jeffrey W BirdDirectorSell238,520$3.77$899,220.40View SEC Filing  
6/20/2014David L AndersonMajor ShareholderSell13,988$4.01$56,091.88View SEC Filing  
1/16/2014Wilfred JaegerDirectorSell96,356$4.86$468,290.16View SEC Filing  
1/15/2014Wilfred JaegerDirectorSell424,956$4.87$2,069,535.72View SEC Filing  
1/10/2014Wilfred JaegerDirectorSell723,900$4.88$3,532,632.00View SEC Filing  
7/15/2013Wilfred E JaegerDirectorSell322,000$5.53$1,780,660.00View SEC Filing  
7/11/2013Wilfred E JaegerDirectorSell178,000$5.51$980,780.00View SEC Filing  
7/5/2013Wilfred E JaegerDirectorSell219,667$5.53$1,214,758.51View SEC Filing  
6/19/2013Wilfred E JaegerDirectorSell2,000$5.50$11,000.00View SEC Filing  
6/18/2013Wilfred E JaegerDirectorSell124,733$5.51$687,278.83View SEC Filing  
6/10/2013Wilfred E JaegerDirectorSell153,600$5.48$841,728.00View SEC Filing  
5/31/2013David L AndersonMajor ShareholderSell266,542$5.72$1,524,620.24View SEC Filing  
5/31/2013Jeffrey W BirdDirectorSell273,181$5.72$1,562,595.32View SEC Filing  
5/22/2013Tillman PearceInsiderSell20,000$5.63$112,600.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Threshold Pharmaceuticals (NASDAQ:THLD)
Latest Headlines for Threshold Pharmaceuticals (NASDAQ:THLD)
DateHeadline logoThreshold Pharmaceuticals, Inc. (THLD) to Release Quarterly Earnings on Monday - July 24 at 8:42 AM logoCORRECTION: Today’s Research Reports on Stocks to Watch: Cara Therapeutics and Threshold Pharmaceuticals, Inc. - July 12 at 2:17 AM logoThreshold Pharmaceuticals, Inc. (THLD) Lifted to Sell at ValuEngine - July 8 at 2:52 PM logoThreshold Pharmaceuticals, Inc. (NASDAQ:THLD) Expected to Post Earnings of -$0.07 Per Share - July 5 at 11:49 AM logoThreshold Pharmaceuticals, Inc. (THLD) Stock Rating Lowered by ValuEngine - June 29 at 11:08 PM logoThreshold Pharmaceuticals (THLD) Clinical Trial TH-CR-417 at the MD Anderson Cancer Center - Slideshow - June 15 at 2:22 AM logoThreshold Pharma (THLD) Confirms 1st Patient Dosed in Immunotherapy Clinical Trial of Evofosfamide & Ipilimumab - June 13 at 10:33 PM logoThreshold Pharmaceuticals Announces First Patient Dosed in Immunotherapy Clinical Trial of Evofosfamide and Ipilimumab - June 13 at 9:33 AM logoZacks: Brokerages Expect Threshold Pharmaceuticals, Inc. (THLD) Will Announce Earnings of -$0.07 Per Share - June 9 at 8:02 AM logoThreshold Pharmaceuticals, Inc. (THLD) Director Buys 510,703 Shares - June 2 at 8:20 PM logoOBI Pharma Announces Acquisition of TH-3424 from Threshold ... - PR Newswire (press release) - June 2 at 3:23 PM logoThreshold Pharma (THLD) Sells TH-3424 to OBI Pharma - June 2 at 2:12 AM logoOBI Pharma Announces Acquisition of TH-3424 from Threshold Pharmaceuticals - June 2 at 2:12 AM logoThreshold Pharmaceuticals, Inc. (THLD) Short Interest Update - May 26 at 7:08 AM logoSHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Threshold Pharmaceuticals, Inc ... - PR Newswire (press release) - May 24 at 8:54 AM logoSHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Threshold Pharmaceuticals, Inc. - THLD - May 23 at 7:35 PM logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Into Whether the Sale of Threshold Pharmaceuticals, Inc. to Molecular Templates, Inc. is Fair to Shareholders - THLD - May 23 at 7:35 PM logoThreshold Pharmaceuticals Reports First Quarter Financial Results - May 16 at 11:59 AM logoThreshold Pharmaceuticals posts 1Q loss - May 16 at 11:59 AM logoThreshold Pharmaceuticals, Inc. (THLD) Announces Quarterly Earnings Results - May 16 at 10:54 AM logoThreshold Pharmaceuticals (THLD) Earns Media Sentiment Score of 0.13 - May 2 at 7:04 PM logoThreshold Pharmaceuticals, Inc. (THLD) to Release Quarterly Earnings on Wednesday - May 1 at 6:50 PM logoThreshold Pharmaceuticals (THLD) Receiving Positive News Coverage, AlphaOne Reports - April 29 at 7:23 PM logoThreshold Pharmaceuticals, Inc. (THLD) Sees Significant Increase in Short Interest - April 28 at 8:56 AM logoThreshold Pharmaceuticals (THLD) Receiving Very Favorable Media Coverage, Report Finds - April 18 at 10:24 AM logoThreshold Pharmaceuticals, Inc. (THLD) Short Interest Up 77.5% in March - April 15 at 7:08 AM logoTHRESHOLD PHARMACEUTICALS INC Financials - April 1 at 6:00 AM logoTHRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits - March 29 at 6:38 AM logoThreshold Pharmaceuticals, Inc. (THLD) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS - March 28 at 9:14 AM logoThreshold Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results - March 27 at 7:25 PM logoTHRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements - March 27 at 7:25 PM logo[$$] Molecular Templates to Combine With Threshold Pharmaceuticals - March 21 at 7:59 PM logoWall Street's M&A Chatter From March 17-19 - March 21 at 9:56 AM logoThreshold Pharmaceuticals To Become Molecular Templates Inc. After Merger - March 20 at 6:20 PM logoThreshold Pharma, Molecular Templates to Merge (THLD) - March 18 at 1:16 AM logoThreshold Pharma (THLD) to Merge with Molecular Templates - March 18 at 1:16 AM logoThreshold Pharmaceuticals and Molecular Templates Agree to Combine - March 17 at 8:14 PM logo6:58 am Threshold Pharma will merge with Molecular Templates in an all-stock transaction; Longitude Capital will invest $20 mln at the close of the transaction, including the receipt of additional equity financing commitments of $20 mln - March 17 at 8:14 PM logoThreshold Pharma to Merge with Molecular Templates - March 17 at 8:14 PM logoTHRESHOLD PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or - March 17 at 8:14 PM logoMerck KGaA predicts stable adj EBITDA in 2017 - March 9 at 2:12 AM logo8:12 am Threshold Pharma enters into a collaboration with the National Cancer Institute to study TH-3424 - December 20 at 3:35 PM logoThreshold Pharmaceuticals and National Cancer Institute to Collaborate on Drug Candidate TH-3424 - December 19 at 9:55 AM logoTechnical Reports on Biotech Equities -- Aurinia Pharma, Threshold Pharma, Regeneron Pharma, and INSYS ... - PR Newswire (press release) - December 9 at 9:45 AM



Threshold Pharmaceuticals (THLD) Chart for Monday, July, 24, 2017

This page was last updated on 7/24/2017 by Staff